Cargando…

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice

Transgenic Balb/c mice expressing the transforming rat HER-2/neu oncogene develop early and multifocal mammary carcinomas. Within the first 5 months of life the tissue-specific expression of HER-2/neu causes a progression in all their 10 mammary glands from atypical hyperplasia to invasive carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nanni, Patrizia, Nicoletti, Giordano, De Giovanni, Carla, Landuzzi, Lorena, Di Carlo, Emma, Cavallo, Federica, Pupa, Serenella M., Rossi, Ilaria, Colombo, Mario P., Ricci, Cinzia, Astolfi, Annalisa, Musiani, Piero, Forni, Guido, Lollini, Pier-Luigi
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2001
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2195980/ https://www.ncbi.nlm.nih.gov/pubmed/11696586

Ejemplares similares

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
por: De Giovanni, Carla, et al.
Publicado: (2019)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells.
por: Nanni, P., et al.
Publicado: (1996)

An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention
por: Cavallo, Federica, et al.
Publicado: (2005)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
por: Coscia, Marta, et al.
Publicado: (2010)

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014)

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
por: De Giovanni, Carla, et al.
Publicado: (2019)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

2011: the immune hallmarks of cancer
por: Cavallo, Federica, et al.
Publicado: (2011)

Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice
por: Calogero, Raffaele Adolfo, et al.
Publicado: (2007)

Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin.
por: De Giovanni, C., et al.
Publicado: (1995)

Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET
por: Pantaleo, Maria A., et al.
Publicado: (2010)

Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination.
por: Nicoletti, G., et al.
Publicado: (1992)

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
por: Landuzzi, Lorena, et al.
Publicado: (2014)

Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(−/−);Il2rg(−/−) Mice and Treatment with PI3K Inhibitor
por: Nanni, Patrizia, et al.
Publicado: (2012)

Control of H-2 expression in transformed nonhaemopoietic cells by autocrine interferon.
por: Nanni, P., et al.
Publicado: (1992)

Modeling the competition between lung metastases and the immune system using agents
por: Pennisi, Marzio, et al.
Publicado: (2010)

Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy
por: Pasello, Michela, et al.
Publicado: (2011)

Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells.
por: De Giovanni, C., et al.
Publicado: (1993)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)

The Promise of Preventive Cancer Vaccines
por: Lollini, Pier-Luigi, et al.
Publicado: (2015)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells.
por: Lauri, D., et al.
Publicado: (1993)

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research
por: Landuzzi, Lorena, et al.
Publicado: (2023)

Wnt signalling in mammary carcinogenesis
por: Speirs, Valerie
Publicado: (2002)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Immunogenicity of rat-neu(+) mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment
por: Sow, Heng Sheng, et al.
Publicado: (2020)

A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model
por: Msaki, Aichi, et al.
Publicado: (2016)

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2010)

Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2021)

In vitro differentiation of rhabdomyosarcomas induced by nickel or by Moloney murine sarcoma virus.
por: Nanni, P., et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_q90j47mk6accrf2kp8719ief05